Alessandro Severino

Alessandro Severino

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1996 in Stem Cells
Verified
Journal Article
Closed access
MAMassimo Aglietta
Massimo Aglietta
PPP. Pasquino
P. Pasquino
FSF. Sanavio
F. Sanavio
ASA. Stacchini
A. Stacchini
ASAlessandro Severino
Alessandro Severino
FGF. Gavosto
F. Gavosto

6 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NPNovella Pugliese
Novella Pugliese
Marco PicardiMarco Picardi
Marco Picardi
AVAnnamaria Vincenzi
Annamaria Vincenzi
CGClaudia Giordano
Claudia Giordano
ALAnna Lucania
Anna Lucania
FPFabrizio Pane
Fabrizio Pane
Background/Objectives: Despite the high complete response (CR) rate to first-line therapy, approximately one-third of patients with advanced-stage Hodgkin lymphoma (HL) eventually relapse. In up to 30–50% of cases, relapses are subclinical, i.e., initially detected only by imaging procedures. However, there is no definitive consensus on the optimal surveillance strategy for high-risk HL patients. Methods: The purpose of this cohort study is to evaluate the long-term outcome of stage II-B/IV HL patients who relapsed under routine imaging surveillance (imaging cohort) compared to those who relapsed under conventional clinical monitoring (standard cohort). Follow-up in the imaging cohort systematically included FDG-PET/CT, ultrasonography, and/or chest X-ray. At relapse, patients were treated with the same approach (salvage therapy and autologous hematopoietic stem cell transplantation [AHSCT]) in both cohorts. Results: A total of 123 high-risk HL patients were assessed at their first relapse: 80 in the imaging cohort and 43 in the standard cohort. The 2-year event-free survival (EFS) was significantly higher in the imaging cohort compared to the standard cohort (70% vs. 37.2%, respectively; p = 0.001). Similarly, the CR rate following salvage treatment was greater in the imaging cohort as compared to the standard cohort (68.8% vs. 41.9%, respectively; p < 0.004). These differences were due to the capability of routine imaging surveillance to detect disease with more limited extension (early onset of clinically silent relapses) as compared to standard clinical monitoring, which was associated with relapsed disease in a more advanced stage. Conclusions: Our findings suggest that routine imaging surveillance in patients with high-risk HL leads to improved EFS detecting relapses, which were characterized by more favorable prognostic factors (low tumor burden), thus enabling the timely administration of salvage therapy.

28 October 2024 in Sclerosis
Verified
Journal Article
Open access
PDF file
ATAssunta Trinchillo
Assunta Trinchillo
ACAntonio Carotenuto
Antonio Carotenuto
ASAntonio Luca Spiezia
Antonio Luca Spiezia
DCDaniele Caliendo
Daniele Caliendo
ASAlessandro Severino
Alessandro Severino
RLRoberta Lanzillo
Roberta Lanzillo
Introduction: Although panniculitis-like T cell lymphoma (SPTCL) and hemophagocytic syndrome (HSP) have been described as complications following immunosuppressive treatments, there are no reported cases of concomitant SPTCL/HSP and multiple sclerosis (MS). Materials and Methods: We describe the case of a patient affected by an aggressive phenotype of relapsing remitting MS, characterized by consecutive severe relapses with no complete remission. He developed panniculitis-like T cell lymphoma (SPTCL) and hemophagocytic syndrome (HSP) after receiving multiple immunosuppressive treatments in sequence. Despite the aggressive nature of these complications, the patient responded well to a combination of Gemcitabine and Cisplatin. Discussion and Conclusions: With this case, we suggest that physicians always consider blood diseases as possible MS therapy complications, especially in the sequencing setting, and also consider uncommon treatments in those with autoimmune predispositions.